Altre lingue Innovent Biologics, Inc.

Azioni

1801

KYG4818G1010

Tempo differito Hong Kong S.E. Altri mercati azionari 09:02:38 19/04/2024			Variaz. 5gg	Var. 1 gen.
33,1 ^HKD	-1,78%		-11,38%	-22,57%

02/04	La domanda di trattamento del cancro endometriale di Hutchmed è stata accettata per la revisione	AN
02/04	HSBC in un pagamento speciale sulla vendita di Canada; vittoria di Astra FDA	AN

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer	17/04
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status	03/04
Hutchmed endometrial cancer treatment application accepted for review	02/04
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination	02/04
HSBC in special payout on Canada sale; Astra FDA win	02/04
Innovent Biologics New Cancer Drug Gets NDA from Chinese Authority	02/04
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	02/04
Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application	02/04
Innovent Biologics' Loss Narrows in 2023 as Revenue Grows	21/03
Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024	07/03
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer	06/03
China Accepts Innovent's Second Drug Application for Lung Cancer Treatment; Shares Slide 6%	05/03
Anheart Therapeutics and Innovent Announces China?s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer	05/03
Innovent Biologics' Phase 3 Trial for Thyroid Eye Disease Treatment Meets Primary Endpoints	20/02
Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease	20/02
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	16/02
Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee	09/02
Innovent Biologics’ New Drug Application for Weight Management Drug Accepted by Chinese Regulator	07/02
Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China	07/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Innovent Biologics, Inc.

Azioni

1801

KYG4818G1010

Altre lingue

Filtri